Pharma Capitalizes on Cancer Genetics | GenomeWeb

Pharmaceutical companies are starting to design clinical trials for cancer treatments using data on cancer genetics to pinpoint which patients are more likely to respond to each drug, according to MIT's Technology Review. Emily Singer writes that doctors are hoping to be able to treat patients with specific drugs according to the genetic profile of their illness, and which mutations are affecting their individual tumors.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nucleic Acids Research this week: nanopore sequencing workflow to detect antibiotic resistance in gut microbes, TSSPlant tool, and more.

Because gene-edited organisms can cross borders, Gizmodo wonders whether there should be an international body to govern their use.

HHS Secretary nominee Tom Price is to go in front of the Senate Committee on Health, Education, Labor and Pensions today, NPR's Morning Edition reports.

Prior to being closed, Theranos' Arizona lab failed an inspection by regulators, according to the Wall Street Journal.